Delivering innovative therapeutic options to improve patient health.

Founded in 2010, Althera develops innovative patient focused medicines to improve patient health.

Our first product Rosuvastatin/Ezetimibe (AL-320) is available to patients in more than 28 countries worldwide including all major European markets.

Althera’s second product Ezetimibe/Atorvastatin tablets (AL-310), is approved in both US and Europe, and is expected to be available to patients in 2022/23.

Therapeutics

Life Sciences

Health Care

Althera

Sanjeev Agarwal

Dr. Debajyoti Ray

Charmaine Dias

James Medley

Research and Development

Quality Assurance and Control Team

Leadership Team

Teams at Althera

Research and Development

Quality Assurance and Control Team

Leadership Team